Indo Us Biotech Limited has informed the Exchange about Copy of Newspaper Publication for Audited Financial Results for the quarter/year ended on 31st March, 2026.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indo Us Biotech Limited has published its audited standalone financial results for FY2026. Total income from operations grew 6.2% year-over-year to Rs 11,049.33 lakhs, while Q4 FY2026 revenue surged 47% to Rs 3,350.41 lakhs compared to Q4 FY2025. However, net profit declined 19.3% to Rs 1,312.29 lakhs for the full year, primarily due to a sharp 203% rise in tax expenses to Rs 79.73 lakhs. Profit before tax also fell 15.8% to Rs 1,392.02 lakhs. EPS dropped from Rs 8.11 to Rs 6.54 per share. Despite lower profitability, other equity increased 24% to Rs 7,248.19 lakhs, indicating retained earnings accumulation.
The company showed revenue growth but profitability declined significantly due to higher tax outgo. While equity grew, the lower EPS and reduced net profit may negatively impact investor sentiment in the near term.